<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20201126049498N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-03-10</date_registration>
      <primary_sponsor>Shahed University</primary_sponsor>
      <public_title>effect of Melissa officinalis in treatment of patient with Rheumatoid arthritis</public_title>
      <acronym></acronym>
      <scientific_title>Pilot evaluation of the anti-inflamation and analgesics effect of oral administration of Melissa officinalis in patients with Rheumatoid arthritis: a double-blind randomized crossover trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-03-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>20</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/54482</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, we used Random Allocation software for randomization. The random sequence of samples was performed equally as Intervention and Placbo groups using this software. For allocation concealment, sealed envelopes were used. In this method, each of the random sequences written on a card and they is placed in the envelopes, respectively. Finally, the lid of the envelopes is glued and placed in a box, respectively. At the registration time, based on the order in which eligible participants enter the study, one of the envelopes of their choice will be opened and their assigned group will be revealed, Blinding description: Bottles of drugs and placebo were coded by an expert one in the research center. Researchers, patients, data collectors, and evaluators assess the outcome, are not aware of the contents of the package and grouping, and samples were delivered as random double-blind to the patient. Patients received the number to their referral and entered the study. The number of patients was randomly selected by computer and divided into two groups.</study_design>
      <phase>2</phase>
      <hc_freetext>Rheumatoid arthritis disease.</hc_freetext>
      <i_freetext>Intervention 1: Melissa officinalis  is a perennial herbaceous plant in the mint family (Lamiaceae). Scientific research of this plant shows that it has anti-inflammatory, analgesic, and anti-depressant effects. Dried M. officinalis leaves after powdering in the mill, were administered to patients as 500 mg capsules twice a day (once every 12 hours) for 8 weeks. Intervention 2: Control group: Ready bread crumbs without any additives, were administered to patients as 500 mg capsules twice a day  (once every 12 hours) for 8 weeks.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All impersonal data of the participants without any name; Information on the main implications and all the information obtained from the research were published in article.

When:
In the relevant article after its publication

To whom:
Everyone who has access to the published article

Conditions:
After publication in the journal

Where to obtain:
Article and Dr Azadeh Mizani as the main researcher   azadeh.mizani@yahoo.com

How to obtain:
An email to that person

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Azadeh Mizani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Floor 2, No. 1471, North Kargar Ave, Enghelab Sq, Traditional medicine clinical trial Research Center, Shahed University</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1417953836</zip>
        <telephone>+98 21 6641 8331</telephone>
        <email>azadeh.mizani@yahoo.com</email>
        <affiliation>Shahed University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Abdolrahman Rostamian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Khomeini Hospital Complex, Qarib Avenue, the end of Keshavarz Boulevard</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۱۴۱۹۷۳۳۱۴۱</zip>
        <telephone>+98 21 6691 1294</telephone>
        <email>ar.rostamian@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patient satisfaction and signing of informed consent form
Diagnosis of patients with moderate Rheumatoid Arthritis Using the  Criteria of the American College of Rheumatology
Patients over 18 years
During the period of the disease up to 15 years
DAS Score between 3-5</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Lack of cooperation of patients
History of Heart, kidney, liver and ... diseases
Pregnancy
Any kind of Immunodeficiency diseases
No other autoimmune diseases</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M06.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Rheumatoid arthritis, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Melissa officinalis  is a perennial herbaceous plant in the mint family (Lamiaceae). Scientific research of this plant shows that it has anti-inflammatory, analgesic, and anti-depressant effects. Dried M. officinalis leaves after powdering in the mill, were administered to patients as 500 mg capsules twice a day (once every 12 hours) for 8 weeks.</i_keyword>
      <i_keyword>Control group: Ready bread crumbs without any additives, were administered to patients as 500 mg capsules twice a day  (once every 12 hours) for 8 weeks.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Evaluation of Disease Activity Score 28 (DAS 28). Timepoint: 2 months after and before treatment. Method of measurement: DAS Calculator software.</prim_outcome>
      <prim_outcome>Evaluation of ESR (Erythrocyte Sedimentation Rate. Timepoint: 2 months after and before treatment. Method of measurement: Using Westergren method.</prim_outcome>
      <prim_outcome>Evaluation of Rheumatoid Factor (RF). Timepoint: 2 months after and before treatment. Method of measurement: Quantitative method with diagnostic kit.</prim_outcome>
      <prim_outcome>Evaluation of CRP (C-Reactive Protein). Timepoint: 2 months after and before treatment. Method of measurement: Quantitative method with diagnostic kit.</prim_outcome>
      <prim_outcome>Evaluation of Anti ccp (Cyclic Citrirullinated Peptide). Timepoint: Before treatment. Method of measurement: ELISA method.</prim_outcome>
      <prim_outcome>Assay of TNF-α (Tumor necrosis factor α). Timepoint: 2 months after and before treatment. Method of measurement: ELISA method.</prim_outcome>
      <prim_outcome>Assay of Interleukin 17 (IL-17). Timepoint: 2 months after and before treatment. Method of measurement: ELISA method.</prim_outcome>
      <prim_outcome>ٍEvaluation of visual analog scale (VAS). Timepoint: 2 months after and before treatment. Method of measurement: Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Evaluation of World Health Organization Quality of Life-BREF (WHOQOL-BREF). Timepoint: 2 months after and before treatment. Method of measurement: Questionnaire.</sec_outcome>
      <sec_outcome>Evaluation of Beck Depression Inventory (BDI-II). Timepoint: 2 months after and before treatment. Method of measurement: Questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahed University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-10-29</approval_date>
        <contact_name>Shahed University Committee for Ethics in biomedical Research</contact_name>
        <contact_address>Opposite to Holy Shrine of Imam Khomeini, Tehran-Qom Freeway Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
